|
Novel, Cross-Sarbecovirus Neutralizing and Binding Monoclonal Antibodies (mAbs) (HJF 660-23)
The repeat emergence of SARS-CoV-2 variants of concern (VoC) with decreased susceptibility to vaccine elicited protection highlights the need to develop vaccine candidates with broad protection. Current invention identified six neutralizing antibodies with broad sarbecovirus cross-reactivity. This finding has applications towards developing next-generation...
Published: 5/9/2025
|
Inventor(s): Kerri Lal, Shelly Krebs, Samantha Townsley, Michael Gordon Joyce, Vincent Dussupt
Keywords(s): Antibody, Coronavirus, Cross-Reactivity, Ferritin, Infectious Disease, Nano-particle, Neutralizing Antibodies, Respiratory, Sarbecovirus, SpFN, Spike Proteins, Vaccines, Variants, Viral
Category(s): Research Tool
|
|
Lymphocyte Antigen 6 (Ly6) Targeted Cancer Immunotherapy (HJF 649-23)
A technology related to using antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) transduced immune cells that selectively targets Ly6 family of proteins overexpressed in cancer cells and has the potential to be effective in treating ovarian, colorectal, gastric, breast, and lung cancer without off-target effects. This HJF technology...
Published: 3/14/2025
|
Inventor(s): Geeta Upadhyay
Keywords(s): Antibody, Antibody Conjugates, Antibody Drug Conjugate, Cancer, CAR, Ly6, Lymphocite Antigen 6
Category(s): Therapeutic
|
|
Immunogens and Vaccine Components Against HIV - (HJF 630-22)
HJF researchers have developed a novel vaccine strategy against HIV-1. These vaccine candidates are designed to elicit broadly neutralizing antibodies that could protect against a wide variety of HIV strains.
Applications and Advantages
Novel vaccine design approach that emulates the diversity observed in HIV-1 infections with multiple founder variants
Vaccine...
Published: 3/14/2025
|
Inventor(s): Morgane Rolland, Eric Lewitus, Hongjun Bai
Keywords(s): Antibody, Assay, bnAbs, CD4, Env, HIV, Vaccines
Category(s): Vaccine, Therapeutic
|
|
Vaccines Against Fentanyl and Fentanyl Analogs - (HJF 561-19)
A technology related to novel fentanyl hapten compounds and their use in the preparation of vaccines against fentanyl and fentanyl analogs is available for licensing.
Applications and Advantages
Novel compounds for use as vaccines against fentanyl and analogs
High immunogenicity that generates fentanyl specific antibodies to reduce its distribution...
Published: 2/24/2025
|
Inventor(s): Gary Matyas, Oscar Torres, Kenner Rice, Eric Bow, Agnieszka Sulima, Arthur Jacobson
Keywords(s): Antibody, Diagnostics, Fentanyl, Therapeutics, Vaccines
Category(s): Diagnostics, Therapeutic, Vaccine
|
|
Shark Antibodies and Shark-Derived Binding Domains Specific for the SARS-CoV-2 Coronavirus - (HJF 581-20)
HJF scientists have developed a series of single variable domain antibodies (nanobodies or VNARs, derived from nurse sharks) specifically targeting SARS-CoV-2 and other betacoronaviruses, thus providing unique therapeutics and diagnostics for COVID-19 and possibly other betacoronavirus infections.
Applications and Advantages
Fully sequenced, grafted...
Published: 2/24/2025
|
Inventor(s): Michael Gordon Joyce, Kayvon Modjarrad, Helen Dooley
Keywords(s): Antibody, Coronavirus, COVID-19, Diagnostics, Sarbecovirus, SARS-CoV-2, Therapeutics
Category(s): Therapeutic, Diagnostics
|
|
Antibody Based Therapy for HIV - (HJF 562-20)
Currently, anti-retroviral therapy (ART) based on controlling viral replication is the most effective treatment for HIV. However, HIV drug resistance can compromise the effectiveness of ART.
Researchers at Uniformed Services University of the Health Sciences (USU) and HJF in collaboration with scientists at Université de Montréal and...
Published: 3/14/2025
|
Inventor(s): Marzena Pazgier, William Tolbert, Dung Nguyen, Andres Finzi, Jonathan Richard
Keywords(s): Antibody, Antibody Conjugates, CD4, Cytotoxicity, HIV, Neutralization, Peptide-Based Mimetic Compounds
Category(s): Therapeutic, Antibody Therapy
|
